This new strategic report from Espicom provides a comprehensive review of current and future treatments for major blood cancer therapy areas: chronic lymphocytic leukaemia, chronic myeloid leukaemia, acute myeloid leukaemia, multiple myeloma and non-Hodgkin's lymphoma.

Over 275 pages of product analysis, market statistics and forecasts Unique market share and 5-year sales forecasts for leading products & pipeline prospects. A comprehensive examination of major blood cancer therapy areas. Critical competitive evaluation and scoring of current and future products.

Providing…

• Detailed analysis and 5-year forecasts for current leading products by value
• A detailed review and assessment of up and coming products
• Unique product assessment and scoring
• An evaluation of the current understanding of blood cancers

THE REPORT COVERS MAJOR BLOOD CANCER AREAS

• Chronic lymphocytic leukaemia
• Chronic myeloid leukaemia
• Acute myeloid leukaemia
• Multiple myeloma
• Non-Hodgkin’s lymphoma

THE MARKET

• Risk factors, how the disease affects patients, diagnosis and stages of the disease
• The market in 2007 and 2012
• Growth drivers and dampeners

PATIENT STATISTICS

• Prevalence
• Diagnosis rates
• Unmet clinical need

CURRENT TREATMENT OPTIONS

• Interventions by type
• Unique five point competitive assessment and scoring of current therapies and companies involved
• 5-year sales forecasts for key products

R&D: DRUGS IN LATE STAGE DEVELOPMENT

• Focus on new classes of drugs and the companies involved
• Unique competitive assessment and scoring of new therapies and companies involved
• 5-year sales forecasts for key products from year of launch

The market for blood cancer drugs will almost double by 2012 at an average year-on-year growth rate of 15%. What are the current and new products which will drive this growth and which are the companies to watch?

The size of the blood cancer market has expanded dramatically in recent years. Historically, its component disorders have been treated with combinations of radiotherapy and conventional chemotherapy, with the vast majority of agents being off-patent and having low overall market values.

However, in recent years the launch of several new products - and in particular Novartis’ Gleevec/Glivec and Genentech/Roche’s Rituxan/Mabthera - has transformed the sales dynamic dramatically. These new targeted therapies have been the mainstay of sales growth in the past decade, and now form the largest component of the market in value terms.

There are two key factors behind this effect: firstly the new targeted agents have led to an improvement in survival rates (which, in the case of chronic myeloid leukaemia, has led to large increases in prevalence), and secondly to their premium pricing, relative to the low-priced generic chemotherapies they are replacing.

Small market, big value

We estimate that although the blood cancers only represent 7% of cancer patient numbers, they represented up to 25% of the oncology market (excluding supportive care) in value terms in 2006.

Unmet clinical need

We believe that considerable further opportunity for growth in the blood cancer market. In each of the major therapy areas, there remains sizeable unmet medical need, giving rise to substantial sales potential for successful products. Additionally, in all therapy areas, conventional chemotherapy is used in some - if not all - patients, and there is a need for new agents with better tolerability.

Research continues to grow the sector

A range of new agents is in development for the treatment of blood cancers - including agents with established mechanisms of action, but with improved tolerability or efficacy - and also novel mechanisms of action. Of these new agents in development, we highlight the HDAC inhibitors and Hsp90 inhibitors as being among the most interesting, though much development remains in the early stages.

Among the products evaluated & forecast

• Chronic lymphocytic leukaemia
  • Rituxan
  • ofatumumab
  • lumiliximab
  • Revlimid
  • Treanda
• Chronic myeloid leukaemia
  • Gleevec
  • Sprycel
  • Tasigna
  • bosutinib
  • panobinostat
• Acute myeloid leukaemia
  • Clolar
  • Cloretazine
  • Dacogen
  • Xanafide
  • midostaurin
• Multiple myeloma
  • Revlimid
  • Velcade
• Non Hodgkin’s lymphoma
  • Rituxan
  • Pixantrone
  • Revlimid
  • ofatumumab
  • Velcade

Questions answered

• What is the prevalence and incidence of chronic myeloid leukaemia and how might this change by 2012?
• Will Celgene be able to maintain its dominance in the multiple myeloma market in the face of Millennium’s Velcade?
• What opportunities remain in the non-Hodgkin’s lymphoma market?

Related Reports:
Prostate Cancer Drug Discoveries: What the Future Holds
Competitor Analysis: TGF-R Agonists and Antagonists
BI for Drug Development: Oracle Introduces Clinical Development Analytics
Asia Pacific Pharma Sector Analysis
CDK Inhibitors Patent Landscape 2009
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine
Notable News in the Life Sciences: 3Q09
Pharmaceuticals Wholesaling in Australia - Industry Risk Rating Report
Blood, Organ & Ambulatory Health Services in the US - Industry Risk Rating Report